Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.65 |
| ▸ | ADA | P00813 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HINT1 | P49773 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2'-B-Methyl-Guanosine SCHEMBL12758165 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL12149502 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL10819905 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL10819882 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL10208618 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL18537403 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL15187539 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL14946249 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL21007207 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B | |
| 2'-B-Methyl-Guanosine SCHEMBL14842089 | 1.00 | ADORA2A (0.65) | ADORA2AADAADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12083185-B2 | Small polymeric carriers for delivery of agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-09-10 | — | — | US | claimed |
| US-20210330808-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | claimed |
| EP-3863609-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2021-08-18 | — | — | EP | claimed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| US-9539276-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | claimed |
| EP-2012799-B1 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX INC (US) | 2016-08-24 | — | — | EP | claimed |
| US-20160038527-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | claimed |
| US-9249173-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, LLC (US) | 2016-02-02 | — | — | US | claimed |
| US-20140356325-A1 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVE COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-12-04 | — | — | US | claimed |
| US-7994143-B2 | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates | CHIMERIX, INC. (US) | 2011-08-09 | — | — | US | claimed |
| EP-2307434-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | claimed |
| US-20100249056-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | CHIMERIX, INC. (US) | 2010-09-30 | — | — | US | claimed |
| WO-2010014134-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARAMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | claimed |
| EP-2012799-A2 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | Chimerix, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| US-20080009462-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | CHIMERIX, INC. (US) | 2008-01-10 | — | — | US | claimed |
| WO-2007130783-A2 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ADORA2A 103/4885ADA 45/4885ADORA3 95/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | ADORA2A 640/4885ADA 216/4885ADORA3 729/4885 |
| US-20160038527-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | ADORA2A 3495/4885ADA 1286/4885ADORA3 2107/4885 |
| US-20140356325-A1 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVE COMPOUNDS | MTAP, NT5C3B, PNP | ADORA2A 93/4885ADA 21/4885ADORA3 196/4885 |
| US-20100249056-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | PNP, TYMP, ENPP1 | ADORA2A 565/4885ADA 29/4885ADORA3 638/4885 |
| US-12083185-B2 | Small polymeric carriers for delivery of agents | CD44, PGF, SLC46A1 | ADORA2A 3965/4885ADA 4194/4885ADORA3 4137/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | ADORA2A 640/4885ADA 216/4885ADORA3 729/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ADORA2A 103/4885ADA 45/4885ADORA3 95/4885 |
| US-20080009462-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | PNP, TYMP, ENPP1 | ADORA2A 565/4885ADA 29/4885ADORA3 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.